Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/cisT790M/cisC797S NSCLC: A Case Report.

The American journal of case reports - 23 Sept 2022

Lee Bing-Jie, Lim Chor-Kuan, Chang Hou-Tai, Zhang Jia-Hao

Abstract excerpt

BACKGROUND Brigatinib is used for anaplastic lymphoma kinase (ALK)-positive lung cancer treatment, and some research showed it was useful in treating triple-mutant epidermal growth factor receptor lung cancer. Clinical trials have shown some potential pulmonary toxicities of brigatinib. The early-onset pulmonary events (EOPEs) of brigatinib are associated with high dosage and older age. The successful treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Methylprednisolone

Share to Organophosphorus Compounds

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 36146910
DOI: 10.12659/AJCR.937209
PMCID: PMC9513817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/cisT790M/cisC797S NSCLC: A Case Report.PMID 36146910Read ↗

Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.Semantic proximity Read ↗

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.Semantic proximity Read ↗

Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.Semantic proximity Read ↗

Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity Read ↗

Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.Semantic proximity Read ↗

Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.Semantic proximity Read ↗

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.Semantic proximity Read ↗

Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.